1. Home
  2. RDHL vs SGLY Comparison

RDHL vs SGLY Comparison

Compare RDHL & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • SGLY
  • Stock Information
  • Founded
  • RDHL 2009
  • SGLY 2001
  • Country
  • RDHL Israel
  • SGLY United States
  • Employees
  • RDHL N/A
  • SGLY 15
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • SGLY
  • Sector
  • RDHL Health Care
  • SGLY
  • Exchange
  • RDHL Nasdaq
  • SGLY Nasdaq
  • Market Cap
  • RDHL 3.9M
  • SGLY 4.5M
  • IPO Year
  • RDHL N/A
  • SGLY 2008
  • Fundamental
  • Price
  • RDHL $1.88
  • SGLY $0.76
  • Analyst Decision
  • RDHL
  • SGLY
  • Analyst Count
  • RDHL 0
  • SGLY 0
  • Target Price
  • RDHL N/A
  • SGLY N/A
  • AVG Volume (30 Days)
  • RDHL 2.9M
  • SGLY 649.0K
  • Earning Date
  • RDHL 09-05-2025
  • SGLY 11-13-2025
  • Dividend Yield
  • RDHL N/A
  • SGLY N/A
  • EPS Growth
  • RDHL N/A
  • SGLY N/A
  • EPS
  • RDHL N/A
  • SGLY N/A
  • Revenue
  • RDHL $9,550,000.00
  • SGLY $2,172,036.00
  • Revenue This Year
  • RDHL $381.91
  • SGLY N/A
  • Revenue Next Year
  • RDHL N/A
  • SGLY N/A
  • P/E Ratio
  • RDHL N/A
  • SGLY N/A
  • Revenue Growth
  • RDHL 157.62
  • SGLY N/A
  • 52 Week Low
  • RDHL $1.06
  • SGLY $0.54
  • 52 Week High
  • RDHL $9.00
  • SGLY $5.49
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 52.80
  • SGLY 33.02
  • Support Level
  • RDHL $1.89
  • SGLY $1.01
  • Resistance Level
  • RDHL $2.61
  • SGLY $1.40
  • Average True Range (ATR)
  • RDHL 0.23
  • SGLY 0.16
  • MACD
  • RDHL 0.01
  • SGLY -0.04
  • Stochastic Oscillator
  • RDHL 22.22
  • SGLY 9.14

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About SGLY Singularity Future Technology Ltd.

Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.

Share on Social Networks: